Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the GORE Conformable TAG® Thoracic Endoprosthesis for Treatment of Acute Complicated Type B Aortic Dissection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Presence of acute complicated type B aortic dissection:~   * Dissection is acute Time from symptom onset to dissection diagnosis ≤14 days~  * Dissection is complicated~   Subject must present with at least one of the following:~  * Rupture in the setting of an aortic dissection defined as hemorrhage outside of the aortic boundaries -which is noted by CT scan (hemorrhage must be differentiated from reactive effusions by the investigator, or if equivocal, having elevated Hounsefield units as determined by the radiologist).~  * Clinical evidence of malperfusion, in the setting of an aortic dissection, defined as:~     * Clinical or radiographic evidence of visceral hypoperfusion.~    * Clinical or radiographic evidence of renal hypoperfusion.~    * Clinical or radiographic evidence of lower extremity hypoperfusion.~    * Clinical or radiographic evidence of spinal cord hypoperfusion.~       * Dissection is type B Entire dissection is distal to the left subclavian artery~      * Primary Treatment Indication is Class 1 Aortic Dissection 46 Classical aortic dissection with intimal flap between true and false lumen with double barrel flow in thoracic aorta~      * Subjects with multiple entry tears are allowed to be enrolled in the study~2. Age 18 to 80 years~3. Primary treatment is endovascular treatment with the CTAG device. Adjunctive treatments may include left subclavian artery revascularization, percutaneous fenestration, aortic stenting, peripheral vessel stenting, surgical fenestration, and/or peripheral artery bypass~4. Proximal landing zone characteristics include:~   * Proximal extent of intended proximal landing zone cannot be dissected~  * Length ≥ 2.0 cm proximal to the primary entry tear~  * Trans-aortic diameter at proximal extent of intended landing zone between 16-42 mm (diameter assessed by flow lumen and thrombus, if present; calcium excluded)~  * Cannot be aneurysmal, heavily calcified, or have excessive intraluminal thrombus~  * Must be native aorta~  * May include left subclavian artery, if necessary~5. Subject is capable of complying with protocol requirements, including follow-up~6. Informed Consent Form is signed by subject or legal representative~Exclusion Criteria:~1. Primary treatment indication is Class 2-5 aortic dissection (intramural hematoma, limited dissection, penetrating atherosclerotic ulcer, iatrogenic dissection, traumatic dissection) 46~2. Concomitant aneurysm/disease of the ascending aorta, aortic arch, or abdominal aorta requiring repair (dissection extension into the abdominal aorta is acceptable)~3. Prior repair of DTA~4. Infected aorta~5. Subject has a systemic infection and may be at increased risk of endovascular graft infection~6. Persistent refractory shock (systolic blood pressure \<90 mm Hg)~7. Bowel necrosis (Bowel necrosis will be characterized by direct observation with surgical exploration, or elevated serum lactate level and CT findings of portal venous gas, free intra-abdominal gas, pneumatosis intramural gas, and poor mucosal enhancement of thickened bowel wall)~8. Renal failure , defined as baseline creatinine ≥ 2.5 mg/dl~9. ASA risk classification = V (Moribund patient not expected to live 24 hours with or without operation)~10. Pregnant female~11. Major surgery within 30 days of treatment (other than left subclavian artery bypass or transposition)~12. Degenerative connective tissue disease, e.g., Marfan or Ehler-Danlos Syndrome~13. Treatment in another drug or medical device study within 1 year of study enrollment~14. History of stimulant abuse, e.g., cocaine or amphetamine, within 1 year of treatment~15. Tortuous or stenotic iliac and/or femoral arteries and the inability to use a conduit for vascular access~16. Planned coverage of left carotid or celiac arteries with the CTAG device~17. The planned endovascular procedure involves alterations to the CTAG device~18. Subject has known sensitivities or allergies to the device materials

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- GORE Conformable TAG® Device Surgical Implant (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).